



HW

USSN: 10/643,679  
Atty. Docket No.: PP001612.0009  
(2300-1612.10)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

April 10, 2007

By: \_\_\_\_\_

*Michelle Z. Brach*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: PALIARD et al.  
U.S. Application No. 10/643,679  
Date Filed: August 18, 2003  
Group Art Unit: 1648  
Examiner: Bao Qun Li  
For: ACTIVATION OF HCV-SPECIFIC T CELLS

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.56 AND §1.97(c)(2)

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The citations listed on the enclosed Information Disclosure Form (Forms PTO/SB/08A and PTO/SB/08B) may be material to the examination of the above-identified patent application. Therefore, Applicant submits these documents in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56 and §1.97(c)(2). The Examiner is respectfully requested to make these citations of official record in the present application and return an initialed copy of the attached Forms PTO/SB/08A and PTO/SB/08B to the undersigned.

The present Information Disclosure Statement is being filed after the period specified in 37 C.F.R. §1.97(b) and before the mailing date of a final action, a notice of allowance, or an action otherwise closes prosecution in the current application. Therefore, we hereby submit the fee under 37 C.F.R. §1.17(p).

No copies of the publications listed on the attached Form PTO/SB/08A or PTO/SB/08B are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No. 10/357,619 to which the above-identified application claims priority under 35 U.S.C. §120.


This Information Disclosure Statement under 37 C.F.R. §1.56 and §1.97(c)(2) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.

The Commissioner for Patents is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR 1.16 and 1.17 to Deposit Account No. 03-1664.


Date: April 10, 2007

Respectfully submitted,

By:

  
Mei Hong  
Agent for Applicants  
Reg. No. 55,276

NOVARTIS VACCINES AND DIAGNOSTICS, INC.  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, CA 94662-8097  
Telephone: (510) 923-5413  
Facsimile: (510) 655-3542



USSN: 10/643,679  
Atty. Docket No.: PP001612.0009  
(2300-1612.10)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

April 10, 2007

By: \_\_\_\_\_

*Michelle L. Ford*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: PALIARD et al.  
U.S. Application No. 10/643,679  
Date Filed: August 18, 2003  
Group Art Unit: 1642  
Examiner: Bao Qun Li  
For: ACTIVATION OF HCV-SPECIFIC T CELLS

INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is an Information Disclosure Statement and accompanying Forms PTO/SB/08A and PTO/SB/08B for the above-identified patent application.


- ☐ In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.
- ☒ In accordance with 37 C.F.R. §1.97(c), also enclosed is:
  - ☒ the fee of \$180.00 as set forth in 37 C.F.R. 1.17(p); or
  - ☐ a statement as specified in 37 C.F.R. §1.97(e).

- ☐ In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. §1.97 (e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.
- ☐ Check No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ for total fee is attached.
- ☒ A return receipt postcard is also enclosed.
- ☒ Please charge \$ 180.00 to Deposit Account No. 03-1664 for the total fee. This paper is being submitted in duplicate.

The Commissioner for Patents is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

By:

  
Mei Hong, Ph. D.  
Agent for Applicants  
Reg. No. 55,276

Date: April 10, 2007

NOVARTIS VACCINES AND DIAGNOSTICS, INC.  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, CA 94662-8097  
Telephone: (510) 923-5413  
Facsimile: (510) 655-3542

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/643,679		
		Filing Date	August 18, 2003		
		First Named Inventor	Paliard et al.		
		Art Unit	1648		
		Examiner Name	Bao Qun Li		
Sheet		of		Attorney Docket Number	PP001612.0009

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Zhang et al., Clinical and Diagnostic Laboratory Immunology, Volume 1 No. 3, pages 290-94 (May 1994).	
		Fournillier et al., Journal of Virology, Volume 73 No. 9, pages 7497-9504 (September 1999).	
		Seong et al., Vaccine, Volume 19 Nos. 20-22, pages 2955-64 (April 2001).	
		Saito et al., Gastroenterology, Volume 112 No 4, pages 1321-1330 (April 1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.